Title |
Forty-Year Journey of Angiogenesis Translational Research
|
---|---|
Published in |
Science Translational Medicine, December 2011
|
DOI | 10.1126/scitranslmed.3003149 |
Pubmed ID | |
Authors |
Yihai Cao, Jack Arbiser, Robert J. D’Amato, Patricia A. D’Amore, Donald E. Ingber, Robert Kerbel, Michael Klagsbrun, Sharon Lim, Marsha A. Moses, Bruce Zetter, Harold Dvorak, Robert Langer |
Abstract |
Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 6 | 4% |
Japan | 2 | 1% |
United Kingdom | 1 | <1% |
Switzerland | 1 | <1% |
Netherlands | 1 | <1% |
China | 1 | <1% |
Unknown | 154 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 37 | 22% |
Researcher | 34 | 20% |
Student > Bachelor | 16 | 10% |
Student > Master | 15 | 9% |
Student > Doctoral Student | 10 | 6% |
Other | 31 | 19% |
Unknown | 23 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 40 | 24% |
Medicine and Dentistry | 38 | 23% |
Biochemistry, Genetics and Molecular Biology | 22 | 13% |
Engineering | 17 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
Other | 18 | 11% |
Unknown | 26 | 16% |